H

Hepion Pharmaceuticals

D
HEPA
USD
-0.03
(-4.6154%)
Market Closed
190.000
Volume
-11.43
EPS
-
Div Yield
-0.096724
P/E
3,595,458.12
Market Cap
Today
-4.6154%
1 Week
-4.615%
1 Month
-2.378%
6 Months
-55.072%
12 Months
-83.938%
Year To Date
-80.864%
All Time
0%

Title:
Hepion Pharmaceuticals

Sector:
Healthcare
Industry:
Biotechnology
Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on the development of drug therapy for the treatment of chronic liver diseases. This therapeutic approach targets fibrosis and hepatocellular carcinoma associated with non-alcoholic steatohepatitis, viral hepatitis, and other liver diseases. Its cyclophilin inhibitor, Rencofilstat, is being developed to offer benefits to address these multiple complex pathologies. Rencofilstat is a pan-cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease.
Do you need help or have a question?